A Phase 1, Open-Label, Multicenter, Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients With Advanced or Metastatic Prostate Cancer
Latest Information Update: 07 Apr 2025
At a glance
- Drugs RO-7656594 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Sponsors Genentech
Most Recent Events
- 13 Apr 2023 Status changed from not yet recruiting to recruiting.
- 11 Apr 2023 New trial record